Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention

Diabetic Medicine

Volumn 19, Issue 9, 2002, Pages 708-723

  Unwin, N ^a,c   Shaw, J ^b   Zimmet, P ^b   Alberti, K G M M ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ACCURACY; AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DYSLIPIDEMIA; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED FASTING GLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PHYSICAL ACTIVITY; POPULATION RESEARCH; PREVALENCE; PROGNOSIS; PUBLICATION; RISK FACTOR; SEX DIFFERENCE; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FASTING; GLUCOSE INTOLERANCE; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0036046668     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00835.x     Document Type: Conference Paper

References (59)

1. Classification and diagnosis of diabetes and other categories of glucose intolerance
2. Pharmacologic therapy for type 2 diabetes mellitus
3. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance
4. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics
5. The rising prevalence of diabetes mellitus and impaired glucose tolerance: The Australian diabetes, obesity and lifestyle study
6. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?
7. Plasma glucose and prediction of microvascular disease and mortality: Evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes
8. Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance
9. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: Poor agreement in the Hoorn Study
10. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-85 World Health Organization diagnostic criteria
11. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population
12. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
13. Will new diagnostic criteria for mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data
14. Age and sex specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts
15. Comparison of the fasting and the 2-hour glucose criteria for diabetes in different Asian cohorts
16. Age and sex specific prevalence of diabetes and impaired glucose regulation in 10 Asian cohorts
17. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
18. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes
19. Risk of diabetes in the new diagnostic category of impaired fasting glucose: A prospective analysis
20. Fasting proinsulin concentrations predict the development of Type 2 diabetes
21. Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil
22. Reproducibility of the diagnosis of diabetes over a 30-month follow-up: The Paris Prospective Study
23. Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: Comparison of 1997 ADA and 1985 WHO criteria
24. Impaired fasting glucose is not a risk factor for atherosclerosis
25. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: The RIAD study
26. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria
27. Sick individuals and sick populations
28. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study
29. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
30. Diabetes and cardiovascular disease. The 'common soil' hypothesis
31. Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease
32. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
33. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
34. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
35. Nonhypoglycemic effects of thiazolidinediones
36. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
37. Logistic regression model predicting the incidence of either diabetes or cardiovascular disease in the San Antonio Heart Study: A score sheet for risk assessment
38. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
39. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: Results of a randomised clinical trial. The STOP-NIDDM randomised trial
40. The STOP-NIDDM Trial: An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus
41. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT Diabetes Study
42. Thiazolidinediones and liver toxicity
43. TRIPOD (Troglitazone In the Prevention of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus
44. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone
45. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: Assessment using nateglinide, a new insulin secretagogue
46. Angiotensin II-receptor antagonists: An overview
47. Predicting impaired glucose tolerance (IGT) among individuals with a non-diabetic fasting glucose value. The San Anotnio Heart Study
48. Performance of an NIDDM screening questionnaire based on symptoms and risk factors
49. Performance of a predictive model to identify undiagnosed diabetes in a health care setting
50. The diabetes risk score: A practical tool to predict type 2 diabetes risk
51. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM
52. Transient impaired glucose tolerance in Pima Indians: Is it important?